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790Atherosclerotic coronary heart
disease (CHD) is a major heri-
table cause of death andmorbidity
worldwide. Recent genome-wide
association studies (GWAS) have
provided novel insights into the
genetic basis of CHD (1–3).
However, these discoveries explain
only a small proportion of disease
heritability, suggesting that fur-
ther clinical and genomic strate-
gies are required to explore the
genetic basis of the disease and to
advance clinical translation.
See page 799
One strategy to enhance
genetic discovery in CHD is to
focus efforts on unique clinical
populations at an increased risk
of disease. Patients with chronic
kidney disease (CKD), repre-
senting over 20 million Ameri-
cans (4), are at high risk for
CHD. Although both traditional
and nontraditional CHD risk
factors are common in patientswith CKD (5), the mechanistic basis for the observed
accelerated atherosclerosis and CHD (6,7) remains poorly
deﬁned. Thus, genetic studies of atherosclerosis in CKD
provide a strategy for identiﬁcation of novel CHD loci that
may also be relevant to the general population.
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eNational Institutes ofHealth (NIH). This workbefore emergence of clinically evident CHD in persons
with CKD (8,9), and is one of the few identiﬁable CHD
predictors after controlling for traditional risk factors and
Framingham risk score. A recent GWAS of CAC scores in
community-based cohort studies of European ancestry (EA)
identiﬁed 2 CAC loci, 9p21 and PHACTR1 (10), also
known for their association with CAD and myocardial
infarction (MI) (3,11). Because the burden of CAC is
increased substantially in persons with CKD, this patient
population may provide speciﬁc insights into mechanisms of
atherosclerosis and vascular diseases (12,13).
We performed the ﬁrst systematic study to examine
candidate genes for CAC in persons with CKD enrolled in
the CRIC (Chronic Renal Insufﬁciency Cohort) study.
Initial validation of CRIC ﬁndings was accomplished in 2
general population cohorts with CAC data. SNPs with
suggestive replication were further analyzed for association
with MI in the PROMIS (Pakistan Risk of Myocardial
Infarction Study).
Methods
Study samples. DISCOVERY SAMPLE: THE CRIC STUDY. Our
CKD study sample was derived from the CRIC study
(N ¼ 3,939), a multicenter, prospective, observational cohort
study of renal and cardiovascular outcomes in patients with
moderate CKD (14). Ethnically diverse adults (21 to 74
years; 46% female; 45% European ancestry [EA], 46%
African ancestry [AA], 5% Hispanic, 4% Asian/Paciﬁc
Islander/Native American; w50% with diabetes mellitus)
with mild to moderate CKD (target estimated glomerular
ﬁltration rate [eGFR] 20 to 70 ml/min/1.73 m2) were
enrolled from 7 clinical centers in the United States between
2003 and 2006 (14,15). In-person follow-up visits are con-
ducted annually. A nonrandom sample of 2,026 underwent
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791paper focuses on genetic associations with CAC in the CRIC
EA and AA subsample in which CAC data and consent for
genetic studies were available (N ¼ 1,509). The CRIC study
protocol was approved by the institutional review boards of
all participating institutions, and study participants provided
written informed consent. Multiple clinical, biochemical, and
imaging variables were assessed on an annual basis as
described in the Online Appendix, Feldman et al. (14), and
Lash et al. (15).
CAC REPLICATION AND EXTENSION SAMPLES. We selected all
SNPs associated with CAC score in CRIC at a threshold of
p < 5  104 (as a suggestive ﬁrst-stage threshold, given the
modest size of our discovery sample) and examined their
associations with CAC phenotypes in the PennCAC (Penn
Coronary Artery Calciﬁcation) sample (EA, n ¼ 2,058;
and AA, n ¼ 502) and the AFCS (Amish Family Calciﬁ-
cation Study) (n ¼ 784), as described in the Online
Appendix, Post et al. (16), and Shen et al. (17). The
PROMIS (Pakistan Risk of Myocardial Infarction Study) is
a case-control study of acute MI in South Asians as
described in the Online Appendix and in Saleheen et al.
(18). In support of our use of PROMIS, genetic variants
found in association with major lipids and CHD risk in
Europeans have been previously replicated in PROMIS (19).
Genotyping. Genotyping (see also the Online Appendix)
in the CRIC, PennCAC, and AFCS studies was performed
using the HumanCVD BeadChip v2 ITMAT/Broad/
CARe (IBC) array (Illumina, San Diego, California). This
gene-centric SNP array includesw50,000 SNPs inw2,100
candidate genes, and was speciﬁcally designed to cover genes
for cardiovascular, metabolic, and inﬂammatory diseases
(20). Genotypes were called using Birdseed v2 as described
(21). Samples from the CRIC study were excluded if any of
the following were present: 1) a sample call rate <0.97; 2)
reduced or excess heterozygosity (inbreeding, jFj <0.2); or
3) cryptic relatedness (PI_HAT identity-by-descent <0.2).
SNPs were excluded within each race separately if the call
rate was <90%; minor allele frequency (MAF) was <1%; or
Hardy-Weinberg equilibrium p value was <0.0001. As
described (17,22), sample and SNP ﬁltering criteria were
similar in PennCAC and AFCS. Genotyping in PROMIS
was conducted on the Illumina 660Quad platform.
Statistical analysis. Data are reported as mean  SD for
continuous variables and as proportions for categorical vari-
ables. All analyses were conducted stratiﬁed by race. A prin-
cipal component (PC) analysis plot for EA andAA samples in
the CRIC study is provided in Online Figure 1. In CRIC,
CAC was analyzed using several CAC traits and associated
modeling techniques, as per published literature (8),
including: 1) CACRes: linear regression of inverse normally
transformed CAC residuals, where residuals were generated
by a) stratifying by sex, b) regressing log (CACþ1) on age, c)
calculating the residuals as the difference between the
observed and predicted values, and d) combining the residuals
across sexes; 2) LogCAC: linear regression of logCAC forindividuals with CAC>0; and 3) separate logistic regressions
for each of 3 clinically relevant CAC cut points (>0, CAC0;
>100, CAC100; and >300, CAC300). Due to the explor-
atory nature of our analyses, we did not use a Bonferroni
adjustment for all models tested. In all models, we adjusted for
CRIC study site and the ﬁrst 10 PCs derived using all available
SNPs, to account for population substructure, whereas for #2
and #3, we additionally adjusted for age, age2, sex, and
interactions for age-by-sex and age2-by-sex. Separate models
were ﬁt for each SNP, and tests of association were based on
the Wald test. First, in order to assess the generalizability of
the CRIC sample, we examined associations with top estab-
lished CAD and CAC loci (3,10), using a nominal signiﬁ-
cance threshold of p < 0.05. All SNPs having suggestive
signal (2-sidedWald test p< 5 104) with CAC in CRIC
were interrogated for association with CAC phenotypes in
PennCAC and AFCS.
In PennCAC, CAC phenotypes were deﬁned and
modeled in an identical manner to CRIC with the exception
of a term for study site. In the family based AFCS, the
Mixed Model Analysis for Pedigree software (17) was used
to estimate the effects of genotype on CAC score for age
and sex. The score was deﬁned as log(CACþ1) and log-
CAC (for individuals with CAC >0), and the model
also included an additional random polygenic component
to account for relatedness in the sample. The lambda
statistic of genomic control inﬂation (23) was calculated
in all models for CRIC-EA (1.00 to 1.04), CRIC-AA (1.04
to 1.09), PennCAC-EA (1.04 to 1.07), PennCAC-AA
(0.96 to 1.03), and AFCS-EA (1.04 to 1.05) (Online
Figs. 2A to 2E). A SNP was considered suggestive if the
associated p value corresponding to a test of no association,
versus the 1-sided alternative that the corresponding coef-
ﬁcient is different than 0 and in the same direction as
observed in CRIC, was >0.05. Top CAC-associated SNPs,
or best proxies if SNP data were not available (linkage
disequilibrium [LD] r2 > 0.6 using SNAP version 2.2) (24),
were analyzed for their association with MI in PROMIS
using logistic regression models that included age, sex,
and the ﬁrst 10 PCs. Because MI is a different trait from
CAC, a 2-sided p value <0.05 was considered statistically
meaningful.
Meta-analysis of summary statistics across race or study in
CRIC and PennCAC applied a weighted z-score method
using METAL (25), as we have previously described (1,22).
All analysis, with the exception of the pedigree analysis for
AFCS, was performed using PLINK version 1.06 or R
version 2.14.1 (26).Results
Baseline characteristics of the CRIC sample. Baseline
clinical and demographic characteristics of the CRIC study
CAC genetic subsample by ancestry and sex are presented in
Table 1. The average age was 57 years, and did not vary
signiﬁcantly by ancestry or sex; 43% were AA, 47% were
Table 1 Baseline Characteristics of the CRIC Genetic Sample With CAC Data
European Ancestry African Ancestry
Male
(n ¼ 469)
Female
(n ¼ 387)
Male
(n ¼ 324)
Female
(n ¼ 329)
Age, yrs 57.9  11.3 57.5  11.3 56.3  11.2 58  10.6
Tobacco and alcohol use
Current smoker 40 (8.5) 29 (7.5) 58 (17.9) 51 (15.5)
Never smoked* 210 (44.8) 207 (53.5) 133 (41.0) 174 (52.9)
Alcohol 376 (80.2) 296 (76.5) 213 (65.7) 170 (51.7)
Cardiovascular disease
Myocardial infarction or coronary revascularization 69 (14.7) 33 (8.5) 39 (12.0) 39 (11.9)
Stroke 34 (7.2) 21 (5.4) 42 (13.0) 44 (13.4)
PAD 23 (4.9) 11 (2.8) 23 (7.1) 19 (5.8)
BP variables
Hypertensiony 378 (80.6) 267 (69.0) 298 (92.0) 305 (92.7)
Systolic BP, mm Hg 121.3  17.1 118.4  18.4 132.2  22.9 131.3  21.4
Diastolic BP, mm Hg 71.4  11 67.1  10.7 77.4  14.6 73  12.3
Lipoprotein and blood variables
Hypercholesterolemiaz 401 (86.0) 265 (69.0) 268 (83.0) 241 (73.0)
Lipid-lowering medication 295 (63.0) 199 (51.0) 182 (57.0) 169 (52.0)
LDL cholesterol, mg/dl 97.1  31.4 107.3  32 104.4  37.2 113.3  37.9
HDL cholesterol, mg/dl 42.7  12 56  16.8 45  13.3 54.3  17.3
Total cholesterol, mg/dl 175.9  39.8 191.3  39.2 181  45 195  48.6
Triglycerides, mg/dl 135 (90.5–202.5) 119 (84–167) 114 (78–170) 105 (78–148)
Adjusted serum calcium, mg/dlx 9.1  0.4 9.2  0.4 9.3  0.4 9.4  0.5
Serum phosphate, mg/dl 3.4  0.6 3.7  0.6 3.6  0.7 3.8  0.6
C-reactive protein, mg/l 1.6 (0.8–3.9) 2.2 (0.9–5.4) 2.1 (1.01–4.97) 4.4 (1.6–9.0)
Fibrinogen, g/l 3.7  1 3.8  0.9 4  1.1 4.5  1.2
Metabolic variables
BMI, kg/m2 30  5.1 30.5  7.8 31.4  5.6 33.9  7.3
Waist circumference, cm 104.7  13.6 101  18.3 105.5  14.8 108  17.4
Diabetes 186 (39.7) 117 (30.2) 150 (46.3) 155 (47.1)
Metabolic syndromek 274 (58.4) 188 (48.6) 192 (59.3) 237 (72)
Blood glucose, mg/dl 109.7  49.7 104.9  44.4 112.4  54.4 112.1  44.5
Hemoglobin A1c, % 6.3  1.4 6.1  1.3 6.7  1.6 6.8  1.7
Kidney function
Adjusted serum creatinine, mg/dl{ 1.6  0.4 1.3  0.4 1.9  0.6 1.6  0.6
eGFR, ml/min/1.73 m2# 51.1  16 51.3  19 49  17 46.2  17
Cystatin-C, mg/l 1.3  0.4 1.3  0.5 1.4  0.5 1.4  0.5
Values are mean  SD, n (%), or median (interquartile range). *Never smoking was deﬁned as <100 cigarettes over lifetime. yHypertension was deﬁned as systolic/
diastolic blood pressure 140 mm Hg or 90 mm Hg, or use of antihypertensive medications. zHypercholesterolemia was deﬁned as use of cholesterol-lowering
medications or total serum cholesterol >200 mg/dl. xAdjusted serum calcium (mg/dl) (calcium adjusted for hypoalbuminemia) ¼ serum calcium (mg/dl) þ
0.8  (4  serum albumin [g/dl]). kMetabolic syndrome was deﬁned using National Cholesterol Education Program Adult Treatment Panel III criteria. {Serum
creatinine was calibrated to the laboratory measurement. #The estimated GFR (eGFR) was calculated using the CRIC study–speciﬁc estimating equation that was
derived in its iothalamate glomerular ﬁltration rate subcohort.
BMI ¼ body mass index; BP ¼ blood pressure; CAC ¼ coronary artery calcium; CRIC ¼ Chronic Renal Insufﬁciency Cohort study; HDL ¼ high-density lipoprotein
cholesterol; LDL ¼ low-density lipoprotein cholesterol; PAD ¼ peripheral artery disease.
Ferguson et al. JACC Vol. 62, No. 9, 2013
Genetics of CAC in Chronic Kidney Disease August 27, 2013:789–98
792female, and 40% had diabetes. The median eGFR was 48
ml/min/1.73 m2. Compared with expectations for similar
age distributions in the general population, the CRIC study
sample was more likely to be overweight and have hyper-
tension (HTN), increased levels of triglycerides, ﬁbrinogen,
and C-reactive protein, and a high proportion had cardio-
vascular diseases at enrollment. Mean CAC scores and the
distribution by 3 cut points (>0, >100, >300) in each of the
ancestry and sex groups are presented in Table 2. In
agreement with prior reports in the CRIC study (12) and the
general population (27), CAC scores tended to be higher in
men and EA. Median CAC scores and the prevalence ofCAC >0 (66%), >100 (39%), and >300 (25%) were
substantially higher than reported for population samples of
similar age and ethnicity (8). Thus, compared with the
general population, this CRIC study sample displayed
increased prevalence of traditional and nontraditional CHD
risk factors as well as a greater burden of subclinical and
clinical atherosclerosis.
Association of established CAC and CAD loci with CAC
in CRIC. The top published GWAS 9p21 allele
(rs1333049C) for CAC (10) was associated in the same
direction with CAC traits in CRIC (e.g., z ¼ 2.81,
p ¼ 0.005 for CAC residual in meta-analysis of AA and
Table 2 Coronary Artery Calciﬁcation (CAC) Scores* in the CRIC Genetic Subsample
European Ancestry African Ancestry
Male
(n ¼ 469)
Female
(n ¼ 387)
Male
(n ¼ 324)
Female
(n ¼ 329)
Mean  SD 531  931 222.3  552 350  821 234  568
Median (IQR) 123 (3.44–642.79) 4.2 (0.0–138.7) 20 (0.0–280.0) 12 (0.0–186.0)
CAC >0 368 (79) 215 (56) 218 (67) 199 (61)
CAC >100 245 (52) 113 (29) 128 (39) 98 (30)
CAC >300 178 (38) 67 (17) 77 (24) 59 (18)
Values are mean  SD, median (interquartile range), or n (%). *Coronary artery calciﬁcation was estimated using Agatston scoring.
IQR ¼ interquartile range.
JACC Vol. 62, No. 9, 2013 Ferguson et al.
August 27, 2013:789–98 Genetics of CAC in Chronic Kidney Disease
793EA; p ¼ 0.03 in EA, p ¼ 0.07 in AA). Similarly,
rs4977574G, a top 9p21 GWAS allele for CAD (3), was
also associated in the same direction with CAC in CRIC
(e.g., z ¼ 3.18, p ¼ 0.001 for CAC residual in meta-analysis
of AA and EA; p ¼ 0.04 in EA, p ¼ 0.01 in AA).
Rare variants in LPA (rs3798220) (3,28) and PCSK9
(rs11591147/R46L) (29) are associated with CHD risk. The
IBC array included these variants or proxies (LD r2 > 0.6).
Despite limited power to detect associations with SNPs of
low frequency, there was suggestive evidence of CAC asso-
ciations with these rare variants in the expected direction of
effect. These ﬁndings were generally consistent across CAC
traits; the strongest association for rs3798220 in LPA was
with LogCAC in EA (beta ¼ 1.1, p ¼ 0.02, MAF ¼ 0.02)
and for rs11591147 in PCSK9 was with CAC0 in EA (odds
ratio [OR]: 3.6, p ¼ 0.14, MAF ¼ 0.009).
Strongest IBC loci for CAC in CRIC. In order to
maximize identiﬁcation of candidate loci for CAC in
the CRIC sample, we tested IBC SNP associations across
multiple CAC trait deﬁnitions within each race separately
as well as in a race-combined meta-analysis. For w45,000
SNPs examined, Online Table 1 shows those SNPs (n¼ 268)
that were associated at p < 5  104 with any CAC trait
within either race or in their meta-analysis. As might be ex-
pected with our relatively small sample size, none of these
SNPs reached the Bonferroni-corrected threshold for the
estimated number of independent SNPs tested on the IBC
array (p < 3  106) (30). Regional plots including recom-
bination rate, LD, and p values for SNPs at selective top
CAC loci in CRIC are presented inOnline Figures 3A to 3D.
Next, we examined these top CRIC CAC SNPs for their
association with CAC in PennCAC interrogating the same
CAC trait and race (or meta-analysis) combinations evalu-
ated in the CRIC sample. We also tested these SNPs for
their associations in AFCS, but in this case, the strongest
available CAC phenotype association is presented because
the AFCS family structure and analysis did not permit an
interrogation of the identical CAC traits and race as those in
CRIC. Summary data for each study are shown in Table 3
for the subset of SNPs that had nominal evidence (effect
in the same direction, 1-sided p < 0.05) for similar effects in
PennCAC or AFCS. Overall, 28 SNPs representing 23
independent loci met these suggestive replication criteria andincluded known CAD and CAC loci (9p21 and COL4A1)
(3,10,31), known HTN and diabetes loci not previously
associated with coronary atherosclerosis (HNF4A, ATP2B1,
ADIPOR2 [32–34]), as well as several loci not previously
reported to be associated with CAC, CAD, or CHD risk
factors. In exploratory meta-analyses of the CRIC and
PennCAC data for these 28 SNPs (Online Table 2), SNPs
at 2 loci (ABCA4 and HNF4A) reached p < 2.38  105,
the Bonferroni-corrected threshold for the number of genes
tested. No locus met the more stringent IBC array SNP-
wide Bonferroni correction (p < 3  106) (30).
Association of suggestive CAC loci with MI in the
PROMIS sample. For SNPs with suggestive CAC asso-
ciation, we observed directionally consistent associations
(alleles associated with greater CAC also increased odds of
MI with 2-sided p < 0.05) with MI in PROMIS for 4 of 23
(17.4%) independent loci (exact binomial test p ¼ 0.026;
null proportion ¼ 0.05 vs. 1-sided alternative that propor-
tion is >0.05) (Table 4). Not surprisingly, the strongest
signal was for SNPs at the 9p21 locus (most signiﬁcant SNP
rs4977574; p ¼ 5.67  1012). Three additional loci,
ATP2B1 (rs11105354; p ¼ 3.3  105), COL4A1 (rs13260;
p ¼ 9.6  104), and ABCA4 (rs3789422; p ¼ 1.7  102),
were associated with MI. Associations at both ATP2B1 and
COL4A exceeded the p value Bonferroni adjustment for
multiple testing of suggestive CAC SNPs (p < 0.0022; 0.05
of 23 independent loci).
Discussion
We sought to identify genes for CAC in patients with
CKD, a population at an increased risk of CHD. We found
that previously identiﬁed loci for CAC and CAD in non-
CKD populations had the expected pattern of associations
with CAC in the CRIC. We also identiﬁed a group of
suggestive loci for CAC in the CRIC study sample, for
which associations were similar in PennCAC or AFCS
datasets. In addition to chr9p21 and COL4A1, previously
shown by GWAS to be associated with CAC and CAD
(3,10), we identiﬁed ATP2B1 (a locus for HTN) (30) and
HNF4A (a locus for high-density lipoprotein cholesterol
[HDL-C] and diabetes) (32,35), previously identiﬁed by
GWAS to be associated with CHD risk factors. Besides
Table 3 Top Associations With CAC Traits in CRIC, With Directionally Consistent Associations in PennCAC or AFCS
SNP Trait Race* Chr Locus Effect Allele
Effect Allele
Frequency
(AA/EA)
CRIC
(N ¼ 1,509)
PennCAC
(N ¼ 2,563)
AFCSx
(N ¼ 784)
b (OR)y SE p Value b (OR)y SE p Valuez b SE p Valuez
SNPs with CAC association in either AA or EA
rs3766332 CAC100 AA 1 PTGFR A 0.15/0.06 0.67 (1.96) 0.19 3.30E04 0.38 (1.46) 0.27 0.08 1.33 0.62 0.01
rs1436606k LogCAC AA 8 SDC2 A 0.92/0.999 1.04 0.29 3.90E04 0.68 0.36 0.03 NA NA NA
rs11236998 CACRes AA 11 PHCA A 0.07/0.06 0.39 0.11 3.60E04 0.01 0.15 0.48 0.29 0.13 0.01
rs7134070 CAC0 AA 12 ADIPOR2 A 0.85/0.99 0.69 (1.99) 0.19 3.20E04 0.33 (1.39) 0.19 0.04 0.50 1.14 0.33
rs4456611 CAC100 AA 18 BCL2 A 0.49/0.50 0.48 (0.62) 0.14 4.10E04 0.19 (0.83) 0.18 0.15 0.31 0.13 0.01
rs3943258 CAC100 AA 18 BCL2 A 0.49/0.46 0.49 (1.63) 0.13 2.80E04 0.10 (1.11) 0.20 0.30 0.31 0.13 0.01
rs2868095k CAC0 AA 20 HNF4A A 0.11/NA 0.96 (2.61) 0.24 7.60E05 0.43 (1.54) 0.22 0.02 0.12 0.08 0.06
rs3789422 CAC0 EA 1 ABCA4 A 0.05/0.04 1.82 (6.18) 0.46 8.50E05 0.52 (1.68) 0.21 0.005 0.19 0.27 0.23
rs12613413 CAC300 EA 2 MAP3K2 A 0.82/0.80 0.54 (0.58) 0.15 3.60E04 0.10 (0.90) 0.12 0.19 0.31 0.19 0.04
rs13386681 LogCAC EA 2 ATOH8 A 0.09/0.07 0.80 0.21 1.60E04 0.27 0.13 0.01 0.10 0.35 0.38
rs4946932 CAC0 EA 6 FOXO3 A 0.75/0.29 0.56 (0.57) 0.14 6.70E05 0.01 (0.99) 0.16 0.48 0.32 0.16 0.02
rs10499276 CACRes EA 6 N/A A 0.09/0.13 0.29 0.07 6.90E05 0.08 0.05 0.05 0.10 0.13 0.21
rs7904918 CAC100 EA 10 ACSL5 A 0.52/0.71 0.44 (1.56) 0.13 3.90E04 0.17 (1.19) 0.09 0.03 0.30 0.17 0.04
rs11105354k CAC100 EA 12 ATP2B1 A 0.90/0.82 0.63 (0.53) 0.15 2.80E05 0.10 (0.90) 0.11 0.17 0.30 0.19 0.05
rs13260 CAC0 EA 13 COL4A1 A 0.23/0.1 0.80 (0.45) 0.20 8.70E05 0.10 (0.90) 0.12 0.19 1.20 0.67 0.03
SNP Trait Race* Chr Locus Effect Allele
Effect Allele
Frequency
(AA/EA) z-Score p Value z-Score p Value b SE p Value
Additional SNPs with CAC association in meta-analysis of AA and EA data
rs12132247 CAC300 Both 1 GNG12 A 0.36/0.32 4.06 5.00E05 0.43 0.38 0.23 0.13 0.03
rs1635502 CAC300 Both 1 EXO1 A 0.32/0.44 3.63 2.80E04 0.41 0.34 0.13 0.07 0.03
rs6667260 CACRes Both 1 ITPKB A 0.41/0.51 3.94 8.00E05 0.26 0.39 0.18 0.11 0.04
rs3768991 LogCAC Both 2 NPAS2 A 0.79/0.48 3.56 3.70E04 1.09 0.14 0.24 0.14 0.04
rs12374310 CAC100 Both 4 PPARGC1A C 0.82/0.60 3.63 2.80E04 1.53 0.06 0.25 0.13 0.03
rs17056112 CAC100 Both 8 ADRA1A A 0.01/0.03 3.59 3.30E04 1.70 0.04 NA NA NA
rs4977574 CAC100 Both 9 9p21 A 0.83/0.49 3.92 9.00E05 0.89 0.18 0.36 0.13 4.00E-04
rs2891168 CAC100 Both 9 9p21 A 0.81/0.49 3.76 1.70E04 0.86 0.19 0.38 0.10 1.60E-04
rs10757278 CAC100 Both 9 9p21 A 0.82/0.49 3.57 3.60E04 0.99 0.16 0.34 0.11 0.001
rs10757274 CAC100 Both 9 9p21 A 0.80/0.49 3.70 2.20E04 0.86 0.19 0.36 0.11 4.00E-04
rs10757272 CAC100 Both 9 9p21 A 0.20/0.51 3.58 3.50E04 0.85 0.20 0.36 0.11 4.00E-04
rs7964239 CAC0 Both 12 BCAT1 A 0.78/0.92 3.65 2.60E04 0.84 0.20 0.37 0.16 0.01
rs2834669 CAC300 Both 21 RUNX1 A 0.92/0.92 3.55 3.90E04 1.96 0.02 0.42 0.23 0.03
*Both ¼ European and African ancestry. yFor continuous variables (LogCAC and CACRes [CAC residual]), the effect is presented as beta (b); for CAC cut points (>0, >100, >300), the effect is additionally presented as the odds ratio (OR). zA 1-sided p value is presented for
PennCAC and AFCS, corresponding to a test of no association versus the 1-sided alternative that the corresponding coefﬁcient is different than 0 and in the same direction as observed in CRIC. xBest AFCS p value from LogCAC or LogCACþ1 analyses. kSNP also reached
p < 5  104 in meta-analysis across race in CRIC.
AFCS ¼ Amish Family Calciﬁcation Study; Chr ¼ chromosome; PennCAC ¼ Penn Coronary Artery Calciﬁcation; SNP ¼ single nucleotide polymorphism; other abbreviations as in Table 1.
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Table 4 Association of Top CAC SNPs* With MI in PROMIS
SNP Racey Chr Locus
Effect
PROMIS
(N ¼ 14,885)
Allele OR 95% CI p Valuez
SNPs with effect estimates in same direction for CAC and MI
rs4977574 Both 9 9p21 A 0.85 0.81–0.89 5.70EL12
rs2891168 Both 9 9p21 A 0.85 0.81–0.89 7.70EL12
rs10757278 Both 9 9p21 A 0.85 0.82–0.89 2.20EL11
rs10757272 Both 9 9p21 A 1.17 1.11–1.22 8.10EL11
rs10757274 Both 9 9p21 A 0.82 0.76–0.88 6.80EL08
rs11105354 EA 12 ATP2B1 A 0.90 0.86–0.95 3.30EL05
rs13260 EA 13 COL4A1 A 0.87 0.80–0.94 9.70EL04
rs3789422 EA 1 ABCA4 A 1.20 1.03–1.40 0.02
rs4946932 EA 6 FOXO3 A 0.96 0.92–1.01 0.09
rs7904918 EA 10 ACSL5 A 1.04 0.99–1.09 0.15
rs2868095 AA 20 HNF4A A 1.03 0.98–1.09 0.23
rs11236998 AA 11 PHCA A 0.96 0.87–1.06 0.46
rs2834669 Both 21 RUNX1 A 1.04 0.94–1.15 0.46
rs12613413 EA 2 MAP3K2 A 0.99 0.94–1.03 0.56
rs7964239 Both 12 BCAT1 A 0.99 0.94–1.04 0.70
rs4456611 AA 18 BCL2 A 0.99 0.95–1.04 0.82
rs1635502 Both 1 EXO1 A 1.00 0.95–1.05 0.90
SNPs with effect estimates in opposite direction for CAC and MI
rs7134070 AA 12 ADIPOR2 A 0.92 0.83–1.01 0.09
rs3766332 AA 1 PTGFR A 0.95 0.90–1.01 0.11
rs12374310 Both 4 PPARGC1A C 1.05 0.98–1.13 0.16
rs10499276 Both 6 LOC729635 A 0.93 0.83–1.03 0.18
rs17056112 Both 8 ADRA1A A 0.94 0.84–1.04 0.22
rs13386681 EA 2 ATOH8 A 1.02 0.97–1.08 0.44
rs6667260 Both 1 ITPKB A 0.99 0.94–1.03 0.58
rs12132247 Both 1 GNG12 A 1.01 0.95–1.06 0.82
rs3768991 Both 2 NPAS2 A 1.00 0.96–1.05 0.86
rs3943258 AA 18 BCL2 A 1.00 0.95–1.04 0.90
*SNPs with suggestive association with CAC in CRIC as per Table 3. Data not available for rs1436606. yBoth ¼ European and African ancestry. zTwo-sided p value. Values in bold are statistically signiﬁcant.
MI ¼ myocardial infarction; PROMIS ¼ Pakistan Risk of Myocardial Infarction Study; other abbreviations as in Tables 1 and 3.
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7959p21and COL4A, the suggestive CAC loci, ATP2B1 and
ABCA4, were associated with MI in the PROMIS sample
further supporting their potential importance in CHD.
CKD imparts a substantial increase in CHD risk (9)
although the mechanisms remain incompletely under-
stood. The CKD milieu might provide a discovery
opportunity for CHD genes and pathways. Indeed, we
found that SNPs at the 9p21 locus, the top GWAS signal
for CAC and CHD in the general population, had the
expected pattern of association with CAC in the CRIC
study sample. Further, despite modest sample size, we
identiﬁed trends for low frequency and rare CHD variants
in LPA and PCSK9 (25,26), with the expected direction
and magnitude of effect, on CAC in the CRIC study.
These ﬁndings support our search for CAC loci in CKD
patients and suggest that this may be 1 strategy to enhance
discovery of novel genes for heart disease. Our top ﬁndings
in the CRIC sample provide preliminary support for the
concept that genes identiﬁed for CAC in CKD may have
relevance to CHD risk in the general population. In
addition to SNPs at 9p21 and COL4A1, top SNPs for
CAC in the CRIC sample reside in loci (e.g., ATP2B1,HNF4A, and ABCA4) that have established genetic asso-
ciations with CHD risk factors.
Several GWAS have identiﬁed ATP2B1 as a locus for
HTN and blood pressure in samples of EA and AA (33,36).
ATP2B1 encodes a plasma membrane calcium-transporting
ATPase that plays a critical role in intracellular calcium
homeostasis by removing bivalent calcium ions from
eukaryotic cells. This suggests a potential role in regulation
of arterial tone and vascular calciﬁcation. Indeed, mice
lacking Atp2b1 in vascular smooth muscle cells had elevated
blood pressure (37) suggesting a protective role in HTN and
CHD. In the CRIC sample, the ATP2B1 rs11105354A
allele that is associated with lower CAC (e.g., OR: 0.53; p ¼
2.8  105 for CAC100) is also the most signiﬁcant
ATP2B1 allele for lower blood pressure and reduced HTN
in a large meta-analysis of EA individuals (33). This same
SNP is in strong LD (r2 ¼ 0.9) with the strongest ATP2B1
variant for HTN in Japanese (36). Furthermore, the
ATP2B1 SNP related to lower CAC also had lower odds of
MI (OR: 0.9, p ¼ 3.3  105) in the PROMIS sample.
Thus, our ﬁndings provide strong support for a role for
ATP2B1 in coronary atherosclerosis and CHD.
Ferguson et al. JACC Vol. 62, No. 9, 2013
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796Given the established GWAS associations with HTN, the
ATP2B1 locus effect on CAC may be mediated through
regulation of vasomotor tone and blood pressure. ATP2B1
might also play a speciﬁc role in regulating arterial calciﬁcation
in the setting of disordered calcium and phosphate metabo-
lism that is characteristic of progressive CKD (38) although
this has yet to be established. Using cross-sectional CRIC
baseline data, we found a weak association of the ATP2B1
rs11105354A allele with increased serum calcium (p¼ 0.02),
but no association with serum phosphorous, baseline blood
pressure traits, or eGFR (data not shown).
Since initial submission of our paper, a GWAS in Han
Chinese has demonstrated that SNPs at the ATP2B1 locus
have genome-wide signiﬁcant associations with clinical
CAD (e.g., rs7136259; p ¼ 5.68  1010) (39). Although
the lead SNP for CAD in the Han has only nominal
associations with CAC in our CRIC data (rs7136259; p ¼
0.01 for CAC100 in CRIC EA), this SNP has low LD in
EA samples with our top CAC-associated ATP2B1 SNP
(rs11105354; r2 ¼ 0.136 in CEU [Utah residents with
ancestry from northern and western Europe]). However,
there is high correlation between these 2 SNPs in Asian
samples (r2 ¼ 0.963 in CHBJPT [Han Chinese in Beijing,
China, and Japanese in Tokyo, Japan]) (LD estimates from
1000 Genomes Project Pilot 1 data using SNAP), sug-
gesting that the CAC and HTN association for the ATP2B1
locus in EA populations overlaps with the CAD ﬁnding in
the Han population. This new report reinforces the signif-
icance of our ﬁndings in CKD and underscores the
importance of this locus in CHD.
Through GWAS, the HNF4A locus has been associated
with HDL-C (40), metabolic dyslipidemia (41), and type 2
diabetes (T2DM) in multiethnic populations (32,42).
HNF4A encodes a nuclear transcription factor that regulates
development and function of the liver, kidney, pancreas, and
intestines (43) and modulates hepatic lipogenesis as well as
apolipoprotein C-III and very low-density lipoprotein
secretion (44). Mutations in HNF4A affect insulin secretion
and have been linked to maturity onset diabetes in the
young (45). In the CRIC, the HNF4A SNP that is asso-
ciated with higher CAC is not in LD with variants that
have published associations with lower HDL-C and higher
odds of T2DM. This may reﬂect differences in ethnic LD
structure because HNF4A SNP associations with CAC in
CRIC were detected in the AA subsample, whereas car-
diometabolic ﬁndings to date for the HNF4A locus have
been in non-AA samples. However, evidence for HNF4A
association with clinical CHD, including within PROMIS,
is lacking.
Many of the suggestive loci for CAC contain genes with
known associations with cardiometabolic traits and pathways.
Besides ATP2B1 and HNF4A, these include the adiponectin
receptor ADIPOR2 (34); PPARGC1, which regulates
PPARG, adipose, and lipids (46); FOXO3, a longevity gene
linked to insulin pathway signaling (47); ACSL5, which
regulates fatty acid metabolism; BCL2 (48) and BCAT2,recently found to associate with T2DM; and ABCA4, a gene
for Stargardt retinal disease that also has suggestive associa-
tion with HDL particle number and size (49). Whether any
of these loci have causal roles in atherosclerosis and CHD
remains to be determined. These results do suggest, how-
ever, that loci modulating cardiometabolic risks that are
exacerbated in CKD might be revealed through the study of
atherosclerosis in patients with CKD.
Our study has several strengths. This is the ﬁrst systematic
search for candidate genes for a coronary atherosclerosis trait
in patients with CKD within the CRIC. The CRIC study is
a rigorously designed, multicenter, National Institutes of
Health–sponsored cohort study of CKD that includes
almost equal numbers of EA and AA individuals and
generates resources for subclinical atherosclerosis, multiple
biomarkers of CKD and CHD risk, as well as incident
CHD events and CKD progression (12,14). The CRIC
study genotyped the IBC array in all eligible participants, in
part to facilitate comparisons with other existing IBC
datasets. Thus, we were able to extend CRIC study ﬁndings
by leveraging independent resources with IBC CAC data-
sets, as well as a large GWAS study of MI.
Study limitations. First, the CRIC study sample size is
relatively small for genetic studies of complex traits. Second,
because of the exploratory focus of our analyses, we applied
nonconservative statistical thresholds that did not meet
criteria for genome-wide signiﬁcance, and we did not
attempt to perform Bonferroni correction for the full extent
of multiple testing. Rather, our approach sought to identify
a group of loci with suggestive evidence for CAC and CHD
risk that warrant further study. Our initial ﬁndings do
provide some support for the potential importance of several
of these loci in cardiometabolic disease. Because our work
tested many different outcome models across race and CAC
phenotypes, we did not run additional models adjusting for
traditional or novel (e.g., phosphate and FGF23 [50,51])
risk biomarkers for CHD in CKD. Future studies will focus
on determining the role of intermediate factors in the
genetic associations with CAC in CKD. We acknowledge
the need for larger studies and targeted replications. Third,
in using CKD as a setting to try to identify CHD loci of
broader relevance, our CAC follow-up in PennCAC and
AFCS was not CKD focused; the PROMIS study also was
not in CKD patients and was focused on South Asians. This
heterogeneity may have limited replication. In support of use
of the PROMIS sample, however, most CHD loci have
consistent associations with MI in European and South
Asian samples (2,18). Finally, although not a direct measure,
studies have shown that CAC provides a quantitative esti-
mate of coronary atherosclerosis (52) and is a useful
predictor of CHD, including in patients with CKD (8,9).
Conclusions
CKD, which imparts a high risk for CHD, may provide
a setting for discovery of genes for heart disease. Using
JACC Vol. 62, No. 9, 2013 Ferguson et al.
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797a CRIC study sample of patients with CKD, we identiﬁed
several loci with suggestive evidence for CAC, some of
which are also associated with MI in a general population
sample. Our ﬁndings support the potential for discovery of
novel pathways involved in CHD through focus on
atherosclerosis traits in patients with CKD.
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